Definium Therapeutics (NASDAQ:DFTX) Sets New 12-Month High – Here’s Why

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) hit a new 52-week high on Monday . The stock traded as high as $40.02 and last traded at $40.02, with a volume of 2749393 shares trading hands. The stock had previously closed at $24.48.

Definium Therapeutics News Roundup

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium’s Phase 3 Emerge trial for DT120 met the primary endpoint and all key secondary endpoints, reinforcing confidence in the company’s lead depression program. Article: Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder
• Positive Sentiment: Robert W. Baird raised its price target on DFTX and maintained an outperform rating, while Needham also lifted its target and kept a buy rating, signaling improving Wall Street sentiment. Article: Analysts Are Bullish on These Healthcare Stocks: Definium Therapeutics (DFTX), Apogee Therapeutics (APGE)
• Neutral Sentiment: The company plans a webcast to discuss the trial data, which may provide more detail on durability, safety, and next steps for the program. Article: Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
• Negative Sentiment: Definium also announced a proposed $500 million public offering, which could pressure the stock if investors focus on dilution and financing needs. Article: Definium Therapeutics, Inc. Announces Proposed Public Offering

Analyst Upgrades and Downgrades

DFTX has been the topic of several analyst reports. Leerink Partners set a $52.00 price target on shares of Definium Therapeutics and gave the stock an “outperform” rating in a research note on Monday. Needham & Company LLC boosted their price objective on shares of Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday. HC Wainwright upped their price objective on shares of Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Piper Sandler restated an “overweight” rating and set a $48.00 target price (down from $49.00) on shares of Definium Therapeutics in a research report on Friday, May 8th. Finally, Oppenheimer set a $60.00 target price on shares of Definium Therapeutics and gave the stock an “outperform” rating in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Definium Therapeutics presently has a consensus rating of “Buy” and an average price target of $46.08.

Definium Therapeutics Price Performance

The stock has a market cap of $3.61 billion, a PE ratio of -14.53 and a beta of 2.37. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15. The company’s fifty day moving average is $23.28 and its 200 day moving average is $18.75.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.23). As a group, sell-side analysts anticipate that Definium Therapeutics, Inc. will post -2.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. boosted its position in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares during the period. Fifth Third Bancorp raised its holdings in shares of Definium Therapeutics by 5,593.2% during the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock valued at $40,000 after buying an additional 3,300 shares during the period. BNP Paribas Financial Markets lifted its position in Definium Therapeutics by 56.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after acquiring an additional 3,020 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in Definium Therapeutics during the 3rd quarter worth approximately $107,000. Finally, Flagship Harbor Advisors LLC acquired a new stake in Definium Therapeutics in the fourth quarter valued at approximately $117,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.